Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults
- 31 October 2010
- journal article
- research article
- Published by Elsevier BV in Thrombosis Research
- Vol. 126 (4), e286-e293
- https://doi.org/10.1016/j.thromres.2010.07.015
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJournal of Thrombosis and Haemostasis, 2008
- Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurrent Medical Research and Opinion, 2008
- Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest, 2008
- Factor Xa or thrombin: is factor Xa a better target?Journal of Thrombosis and Haemostasis, 2007
- Factor Xa or thrombin: Is thrombin a better target?Journal of Thrombosis and Haemostasis, 2007
- Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamberThrombosis and Haemostasis, 2007
- Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studiesThrombosis and Haemostasis, 2007
- An Overview of the Structure and Function of ThrombinSeminars in Thrombosis and Hemostasis, 2006
- XimelagatranDrugs of Today, 2006
- Effects of the Oral Direct Thrombin Inhibitor Ximelagatran on P-Selectin Expression and Thrombin Generation in Atrial FibrillationPathophysiology of Haemostasis and Thrombosis, 2003